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Abstract Central nervous system glial cells release and
respond to nucleotides under both physiological and patho-
logical conditions, suggesting that these molecules play key
roles in both normal brain function and in repair after
damage. In particular, ATPreleased from astrocytes activates
P2 receptors on astrocytes and other brain cells, allowing a
form of homotypic and heterotypic signalling, which also
involves microglia, neurons and oligodendrocytes. Multiple
P2X and P2Y receptors are expressed by both astrocytes and
microglia; however, these receptors are differentially
recruited by nucleotides, depending upon specific patho-
physiological conditions, and also mediate the long-term
trophicchanges ofthese cellsduringinflammatory gliosis. In
astrocytes, P2-receptor-induced gliosis occurs via activation
of the extracellular-regulated kinases (ERK) and protein
kinase B/Akt pathways and involves induction of inflamma-
tory and anti-inflammatory genes, cyclins, adhesion and
antiapoptotic molecules. While astrocytic P2Y1 and P2Y2,4
are primarily involved in short-term calcium-dependent
signalling, multiple P2 receptor subtypes seem to cooperate
to astrocytic long-term changes. Conversely, in microglia,
exposure to inflammatory and immunological stimuli results
in differential functional changes of distinct P2 receptors,
suggesting highly specific roles in acquisition of the
activated phenotype. We believe that nucleotide-induced
activation of astrocytes and microglia may originally start as
a defence mechanism to protect neurons from cytotoxic and
ischaemic insults; dysregulation of this process in chronic
inflammatory diseases eventually results in neuronal cell
damage and loss. On this basis, full elucidation of the
specific roles of P2 receptors in these cells may help exploit
thebeneficial neuroprotective features ofactivated glia while
attenuating their harmful properties and thus provide the
basis for novel neuroprotective strategies that specifically
target the purinergic system.
Key words adeninenucleotides.astrocytes.calcium-
mediatedcommunication.microglia.neuroprotection.
oligodendroglia.P2receptors.reactivegliosis.sugar
nucleotides.uracilnucleotides
Abbreviations
α,βmeATP alpha-beta-methylene-ATP
AA arachidonic acid
bFGF basic fibroblast growth factor
βγmeATP beta-gamma-methylene-ATP
COX-2 cyclooxygenase-2
ERK1/2 extracellular-regulated kinases 1/2
GFAP glial fibrillary acidic protein
LPS lipopolysaccharide
2meSATP 2-methylthio-ATP
OPs oligodendrocyte progenitors
PLA2 phospholipase A2
PLC phospholipase C
PLD phospholipase D
PPADS pyridoxalphosphate-6-azophenyl-20-40-disul-
phonic acid
TNP-ATP 20,30-O-(2,4,6-trinitrophenyl)-ATP
Introduction
The roles of extracellular nucleotides as signalling mole-
cules are now well established. ATP (and maybe other
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ters at many central and peripheral synapses, from which it
can be released upon presynaptic depolarising stimuli via a
regulated secretion pathway (for review, see [1]). Released
nucleotides activate specific membrane receptors, which
mediate highly specific and diversified functions in many
organs and systems: the seven ligand-gated P2X1–7 receptor
channels and the eight G-protein-coupled 7-transmembrane
spanning P2Y receptors (P2Y1,2,4,6,11,12,13,14 receptor sub-
types) [2–4].
In recent years, evidence has been accumulating to
suggest that nucleotides are also released from nonneuronal
cells (e.g., circulating platelets and erythrocytes, inflamma-
tory cells, exercising muscle cells, hypoxic cardiomyocytes)
and, within the central nervous system, from glial cells. It
was initially believed that release of nucleotides from glia
could only occur under pathological conditions (e.g., brain
ischaemia and trauma) as a consequence of leakage from the
cytosolic nucleotide pool due to loss of membrane perme-
ability under milder stress or hypoxic conditions, or as a
result of nucleic acid degradation upon cell death due to
persistent or stronger insults. It is now known that
significant nucleotide release from glia (astroglia, in
particular) can also occur under physiological conditions,
suggesting that these molecules not only participate in brain
repair and recovery after damage but may also play key
roles in normal brain function (see also below).
As mentioned above, the highly specific functions of
nucleotides are mediated by the activation of P2X and
P2Y receptors on target cells. While P2X receptors are
believed to mainly respond to ATP and ADP, the P2Y
receptor family currently encompasses (1) adenine nucle-
otide-responding receptors (P2Y1,P 2 Y 11,P 2 Y 12 and
P2Y13 subtypes), (2) uracil nucleotide-preferring receptors
responding to either UTP or UDP (human P2Y4, P2Y6), (3)
receptors of mixed selectivity responding to both ATP and
UTP (P2Y2, rodent P2Y4), and (4) the recently recognised
P2Y14 receptor, which exclusively responds to sugar
nucleotides [4]. P2X receptors are channels for sodium
and calcium and may occur as homo- or heterooligomers of
more than one subunit characterised by different pharma-
cological profiles (see [3]). P2X7 subunits do not hetero-
oligomerise (see [3]), and are unique in mediating apoptosis
and necrosis of several cell types, including glial cells and
possibly neurons. P2Y receptors are coupled to several
different transduction pathways, including activation of
phospholipase C (PLC), inositol-phosphate formation and
release of calcium from intracellular stores in the case of
P2Y1,2,4,6,11 receptors [4] and inhibition of cAMP forma-
tion in the case of P2Y12,13,14. Additional transduction
mechanisms have been recently reported (e.g., [5]).
Both P2X and P2Y receptors are expressed on all types
of brain cells, including neurons, astrocytes, microglial cells
and oligodendroglia. In neurons, the P2X2, the P2X4/P2X6
and P2Y1 receptors appear to be the predominant receptor
types [1]. While P2X receptors mediate fast synaptic
responses, P2Y receptors have been proposed to mediate
slow changes of neuronal membrane potential in response
to non–synaptically released ATP. Localisation of these
receptors may be at the axon terminals (presynaptic) or the
somato–dendritic region (postsynaptic). While presynaptic
P2 receptors may be either excitatory (P2X) or inhibitory
(P2Y), postsynaptic P2 receptors appear to be without
exception excitatory. For more details on the roles of
neuronal P2 receptors, the reader is referred to recent
authoritative reviews in the field (e.g., [1, 6]). Here, we aim
at critically revising the literature on the presence and roles
of P2 receptors in glial cells, with special focus on astroglia.
We will, however, briefly summarise the most important
findings on P2 receptors in oligodendrocytes and Schwann
cells and microglia.
Functional roles of P2 receptors in oligodendrocytes
and Schwann cells
Oligodendrocytes and Schwann cells are the myelin-
forming cells of the central (CNS) and peripheral (PNS)
nervous systems, respectively, that wrap layers of myelin
membrane around axons to insulate them for impulse
conduction. Early studies by Fields and Stevens suggested
that action-potential firing in axons can regulate maturation
of surrounding immature oligodendroglia and Schwann
cells and that purinergic signalling, mediated by the
activity-dependent axonal release of ATP and subsequent
hydrolysis to adenosine, is one of the principal mechanisms
of activity-dependent communication between axons and
myelinating glia [7, 8]. In a more recent study, Agresti and
coworkers characterised the expression of P2 receptors and
their functional activity in rat oligodendrocyte progenitors
(OPs) [9]. They found that these cells express different
types of P2 receptors and that nucleotide-induced Ca
2+
raises are mainly due to the activation of P2X7 ionotropic
and ADP-sensitive P2Y1 metabotropic receptors. They also
showed that ATP and ADP stimulate the migration and
differentiation of these progenitor cells and inhibit their
mitogenic response to platelet-derived growth factor, thus
confirming an important regulatory role for the adenine-
nucleotide-preferring P2Y1 receptor subtype.
P2 receptors may also influence oligodendrocyte func-
tion at later developmental stages. Addition of ATP analogs
to already differentiated oligodendrocytes in coculture with
dorsal root ganglion cells produced significantly more
myelinated axons [10]. Experiments with more selective
P2 receptor agonists showed that the P2Y receptor agonist
UTP (300 μM) was ineffective (90.1% ± 13.9% relative to
control) whereas the P2X receptor agonist alpha-beta-
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tion (169.4% ± 37.0%). Considerable additional research
will be required to fully identify the specific P2 receptor
subtypes responsible for this effect, but these initial findings
do not provide support for involvement of the P2X7, P2Y2,
or P2Y4 receptor subtypes in increased myelination.
Recently, a link between electrical impulse activity in
axons, astrocytes and myelination that is mediated by the
cytokine leukaemia inhibitory factor (LIF) has been
demonstrated. In particular, LIF is released by astrocytes
in response to ATP liberated from axons firing action
potentials (see also Figure 2), and LIF promotes myelina-
tion by mature oligodendrocytes [10]. These results reveal a
new mechanism by which action potentials influence
myelination that involves unexpected interactions between
astrocytes and myelinating glia and between purinergic and
cytokine signalling.
Globally, these findings suggest that ATP (and maybe
other nucleotides), which is released in high amounts under
inflammatory conditions and following cell death (see also
below), might regulate remyelination processes in inflam-
matory demyelinating diseases of the CNS, such as
multiple sclerosis.
Functional roles of P2 receptors in microglia
Microglial cells, which react to almost any type of
pathological conditions, are thought to play a major role
in the immune response that occurs in the CNS. Upon
activation, microglial cells acquire features of cytotoxic and
phagocytic cells, therefore taking part in the remodelling of
the nervous system tissue following insults. Among various
substances, including growth factors, cytokines, chemo-
attractants and neurotransmitters [11], extracellular ATP has
been indicated as a key messenger in microglial activation.
Functional responses to nucleotides have been reported in
microglialcellsbothinculture[12–14] and in situ [15]. The
effects induced by ATP in microglial cells are complex (for
review, see [16]). As first analysed in culture, purinergic
receptor activation triggers induction of a nonselective
cationic and a K+ conductance and leads to an increase in
cytosolic [Ca
2+][ 14]. Pharmacological screening indicates
that microglial cells express both P2Y and P2X receptors
(see also below). As studied in cell culture, both non-
stimulated and stimulated microglial cells express puriner-
gic receptors. In cultured microglia, activation of P2X7
receptors by astrocyte-derived ATP provokes release of
interleukin (IL)-1β and also triggers release of plasminogen
[12, 17]. Challenge of cultured microglia with lipopolysac-
charide (LPS) induced release of tumour necrosis factor
alpha (TNFα), IL-6, IL-12 and macrophage inflammatory
protein 1α. All these parameters were reduced in the
presence of purinergic ligands, suggesting that purinergic
receptor activation may attenuate indicators of microglial
activation [18]. On the other hand, LPS can per se
differentially regulate the responsiveness of P2 receptors
(see also below). To determine which subtype(s) of P2
receptors mediate(s) the response of microglia to nucleo-
tides, we recently assessed the presence and activity of P2
receptor subtypes in the mouse microglial N9 cell line. All
members of the P2 receptor family were found to be present
in these cells at mRNA and/or protein level. The function-
ality of these receptors was assessed by analysing the
calcium responses induced by specific P2X/P2Y agonists.
Data suggested that, under resting conditions, a major
contribution to [Ca
2+]i increases was given by the P2X7
receptor. Among P2Y receptors, P2Y1 and P2Y2/4 play a
prominent role, and P2Y6, P2Y12/13 and P2Y14 may also
contribute [19]. Importantly, we showed that N9 microglial
cells maintain a P2 receptor profile comparable with that of
primary microglial cells isolated from rodent embryo, hence
validating this cell line as an adequate model to study
regulation of microglia by purines. Changes in P2 receptor
functionality were induced by exposure of cells to the
bacterial endotoxin lipopolysaccharide (LPS), a widely
utilised experimental tool to mimic microglia-cell activation
in vitro [19]. LPS increased P2Y6 and P2Y14, decreased
P2X7 and left P2Y1 and P2Y2,4 receptor activity unchanged.
These differential changes suggest selective roles for specific
P2 receptor subtypes in the acquisition of the final activated
microglia phenotype. Recently, a role for purinergic micro-
glial receptors in tactile allodynia after nerve injury has been
suggested [20]. Pharmacological blockade of spinal P2X4
receptors reversed tactile allodynia caused by peripheral
nerve injury without affecting acute pain behaviours in naive
animals. After nerve injury, expression of P2X4 increased
strikingly in hyperactive microglia (but not in neurons or
astrocytes) of the ipsilateral spinal cord. Intraspinal admin-
istration of P2X4 antisense oligodeoxynucleotide decreased
induction of P2X4 and suppressed tactile allodynia after
nerve injury. Conversely, intraspinal administration of micro-
glia in which P2X4 had been induced and stimulated
produced tactile allodynia in naive rats. Taken together,
these findings suggest that microglial P2 receptors may
represent novel interesting therapeutic targets for inflamma-
tory neurological diseases characterised by abnormal micro-
glial response, including pain.
Role of extracellular nucleotides and their receptors
in astrocytes
Astrocytes play a pivotal role in CNS physiopathology. These
cells participate to neuronal migration during brain develop-
ment [21] and express neurotransmitter transporters and re-
ceptors (including P2 receptors, see also below), thus actively
participating in neurotransmission [22–24]. Astrocytes also
Purinergic Signalling (2006) 2: 595–604 597releaseandrespondtochemokinesandcytokines[25, 26]a n d
are capable of intense metabolic activity and proliferation
(“reactive astrogliosis”) during diverse immune/inflammatory
brain diseases (e.g., multiple sclerosis, Alzheimer_sd e m e n t i a ,
tumours and neurodegenerative and prion diseases) (for
review, see [27] and references therein). There is hence a
growing interest in the characterisation of endogenous factors
regulating short- and long-term astroglial cell function under
both physiological and pathological conditions.
Involvement of extracellular nucleotides in homotypic
and heterotypic short-term calcium-dependent
signalling in the brain
In recent years, one of the most exciting developments in the
field of purinergic transmission has been the demonstration
that ATP is the dominant messenger mediating intercellular
communication in the brain and that this occurs via
activation of P2 receptors on astrocytes. Several years ago,
we and other groups demonstrated that exposure of mam-
malian brain astrocytes to adenine or uracil nucleotides
resulted inconcentration-dependent increasesof intracellular
calcium ([28]; for review, see [29]). This effect was
antagonised by non–selective P2 receptor antagonists such
as suramin and pyridoxalphosphate-6-azophenyl-20-40-
disulphonic acid (PPADS), thus confirming the involve-
ment of extracellular P2 receptors [28]. More or less in the
same period, seminal work by Guthrie and coworkers [30,
31], Newman and Zahs [32] and Haydon [29] demonstrated
that mechanical stimulation of a glial cell evoked a local
elevation of intracellular calcium that subsequently propa-
gated to neighbouring cells. These calcium waves were
initially thought to spread as a result of gap-junction
metabolic coupling via diffusion of inositol-tris-phosphate
through neighbouring cells. This mechanism indeed
explained short-term signalling, but a diffusible factor was
showntobenecessaryforlong-rangecalciumsignalling,and
this factor was later identified as ATP [29] (see Figure 1).
These findings were then confirmed by several other groups,
and the molecular mechanisms responsible for ATP release
from astrocytes were characterised in detail. Seminal work
by Coco et al. [33] demonstrated that ATP released from
astrocytes could also serve as a signalling molecule for
other types of brain cells. Specifically, these authors
showed that, in astrocyte-microglia co–cultures, mechani-
cal or neurotransmitter (bradykinin) stimulation resulted in
calcium elevation in astrocytes, which was followed
immediately afterwards by calcium elevation in neighbour-
ing microglia. This effect was blocked by the ATP-
degrading enzyme apyrase and by P2 receptor antagonists,
thus confirming that ATP was indeed the diffusible factor
involved. Coco et al. [33] also demonstrated that astrocytes
could concentrate ATP in vesicles (which were distinct
from glutamate-containing vesicles), from which ATP
could be released via a regulated secretory pathway even
under pseudo–physiological conditions.
The importance of ATP in mediating cell-to-cell com-
munication in the brain has been recently confirmed in vivo
in transgenic mice in which all microglia are fluorescently
labelled. By utilising time-lapse two-photon imaging of the
intact mouse cortex, Davalos et al. [34] showed that the fine
termini of microglial processes are highly dynamic. Upon
traumatic brain injury, microglial processes rapidly and
autonomously converged on the site of injury, establishing
a potential barrier between the healthy and injured tissue.
This rapid chemotactic response could be mimicked by
local injection of ATP and could be inhibited by the ATP-
hydrolysing enzyme apyrase or by purinergic receptor
blockers. The microglial response was also abolished by
connexin channel blockers, which are highly expressed in
astrocytes and inhibit ATP release from these cells. This
represents the first in vivo demonstration that ATP release
from brain-damaged tissue and surrounding astrocytes
mediates a rapid microglial response towards injury.
Since the first demonstration that ATP could act as
signalling molecule in short-term calcium-dependent cell-
to-cell communication in the brain, there has been a lot of
interest in the characterisation of the specific P2 receptor
subtypes involved in this action. In this respect, we
characterise the expression and functionality of P2 recep-
tors in rat cortical primary astrocytes [35]. Reverse
transcriptase polymerase chain reaction (RT-PCR) and
Western blot analysis showed that, with the exception of
the P2X6 receptor, these cells express all other P2X (i.e.,
P2X1–5 and P2X7) and P2Y receptors (i.e., P2Y1, P2Y2,
P2Y4, P2Y6, P2Y12 and P2Y14) cloned from rodent tissues
(P2Y11 was not investigated based on bioinformatics data,
suggesting that this receptor is not present in rat and murine
genomes). The P2Y13 receptor (which we originally cloned
and characterised from rat tissues in 2004, see [36]) was
also found to be expressed at levels comparable to those of
the other known P2Y receptors. Thus, rat brain astrocytes
surprisingly express a nearly full panel of P2 receptors.
Such a large repertoire of P2 receptors is in line with the P2
receptor heterogeneity reported in several other tissues and
cells (e.g., [19, 37], suggesting that specific receptor
subtypes are differentially recruited and/or inserted into
the plasma membrane, depending upon the cell functional
state and specific pathophysiological conditions. In line
with this hypothesis, single-cell image analysis showed that
in rat primary astrocytes, only some of the expressed P2X
and P2Y receptors are functionally coupled to increases of
[Ca
2+]i. While ATP induced rapid and transient [Ca
2+]i in-
creases (counteracted by the P2 antagonists suramin,
PPADS and oxidised ATP), the P2X1/P2X3 agonist
α,βmeATP produced no changes [35]. Conversely, the
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phosphate (BzATP) markedly increased [Ca
2+]i and induced
the formation of the P2X7 pore, as assayed by ethidium
bromide (EtBr) uptake. ADP and 2-methylthio-ATP
(2meSATP) also produced [Ca
2+]i increases antagonised
by the P2Y1 antagonist MRS2179 [35]. Some cells also
responded to UTP but not to UDP. Significant responses to
the sugar– nucleotides UDP-glucose and UDP-galactose
were also detected, which represented the first functional
response reported for the P2Y14 receptor in a native system.
Based on agonist preference of known P2 receptors, we
concluded that in rat cortical astrocytes ATP-induced
calcium rises are at least mediated by P2X7 and P2Y1
receptors; additional receptors (i.e., P2X2, P2X4, P2X5,
P2Y2, P2Y4 and P2Y14) may also contribute. Our results
highlighting a role for P2Y1 and P2Y2 receptors in short-
term calcium signalling are consistent with data from
Gallagher and Salter [38], showing that these receptors are
both necessary for propagation of calcium waves in rat
spinal cord astrocytes and in human 1321N1 astrocytoma
cells. These authors also showed that calcium waves
propagating through P2Y2 travel faster and further. Inter-
estingly, apyrase accelerated propagation through P2Y1 and
blocked propagation through P2Y2, suggesting that the
level of expression of nucleotidases may regulate the extent
of activation of the two receptors, thus affecting the
characteristics of calcium waves. It must be emphasised,
however, that these studies have been performed on human
astrocytoma cells heterologously expressing these receptor
subtypes. Our data on the rat primary astrocytes suggest a
role also for the P2X7 receptor, in line with previous
findings demonstrating that treatment of rat astrocytic
cultures with BzATP increased influx of extracellular Ca
2+
and [Ca
2+]i [39]. However, no study has investigated the
possible role of this receptor subtype in in vivo short-term
calcium-dependent signalling.
In conclusion, these findings demonstrate that upon
mechanical or neurotransmitter stimuli, brain astrocytes can
release and respond to ATP with a propagating wave of
intracellular calcium increases, allowing a homotypic,
astrocyte-to-astrocyte, communication as well as a hetero-
typic signalling, which involves adjacent brain cells,
including neurons, oligodendrocytes and microglia [40].
Involvement of extracellular nucleotides in long-term
morphological and functional changes of astrocytes
(reactive astrogliosis)
Brain astrocytes are also known to undergo reactive astro-
gliosis, a phenomenon characterised by astroglial prolifera-
tion, cellular hypertrophy, enhanced synthesis of
Figure 1 Stimulation of glial cells from the retina evokes a radially
propagating wave of elevated calcium. (a) Mechanical stimulation of a
glial cell in the centre of the field of view evoked a local elevation of
Ca
2+. Subsequently, this Ca
2+ elevation propagated to neighbouring
cells. In this sequence, images were acquired at 0.93-s intervals, and
the white overlay image shows the leading edge of the wavefront.
(b) Putative mechanism for glial Ca
2+ wave generation. Ca
2+ is
released from internal stores in response to elevated internal inositol-
1,4,5-trisphosphate [Ins(1,4,5)P3]. Ins(1,4,5)P3 can diffuse to neigh-
bouring cells through gap junctions to cause short-range signalling.
Long-range calcium signalling requires the release of ATP, which
causes the regenerative production of Ins(1,4,5)P3 and further release
of ATP from neighbouring astrocytes. Reproduced with permission
from [29].
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elongation of glial fibrillary acidic protein (GFAP)-positive
astrocytic processes (for review, see [27]). Sustained inflam-
matory astrogliosis is detected in the mammalian brain
following various kinds of traumatic or hypoxic insults (e.g.,
stroke), as well as chronic neurodegenerative and demyelin-
ating disorders (Alzheimer_s, Parkinson_s, Huntington_s
diseases and multiple sclerosis; for reviews, see [27, 41].
Reactive glia seems to function as a double-edged sword for
neurons.Onone side,reactiveastrocytescanimpedeneuronal
survival and regeneration by forming scar tissue and
synthesisingneurotoxicmolecules [includingcytokines,nitric
oxide (NO) and arachidonic acid (AA) metabolites] [41].
However,theneteffectofglia-mediatedneuroinflammationis
sometimesbeneficial[41]. For example, in the PNS, inflam-
mation is necessary for the successful regeneration that is
impeded in the CNS, and loss of astrocytes impairs recovery
[42]. Moreover, activated astrocytes are needed for axonal
growth and guidance, to promote repair, produce energy
substrates and neurotrophins, act as free radicals and
glutamate scavengers, restore the blood–brain barrier and
promote neovascularisation and neurogenesis—i.e., the gen-
eration of new neurons that continues throughout life and
contributes to brain recovery after damage. Interestingly,
while acute insults trigger “compensatory” neurogenesis,
chronic neuroinflammation is detrimental to regeneration
[43]. Thus, inflammatory gliosis in the brain likely starts as
a time- and site-specific defence mechanism that could later
evolve as a destructive and uncontrolled reaction, thus
contributing to brain damage.
Extracellular nucleotides have been implicated as en-
dogenous triggers of reactive astrogliosis. Upon trauma or
ischaemia, brain cells are exposed to elevated concentra-
tions of nucleotides and nucleosides for prolonged periods
as a result of leakage from the nucleotide cytosolic pool
(due to loss of membrane permeability) or nucleic acid
degradation upon cell death due to persistent or stronger
insults. Purines and pyrimidines can indeed produce all the
hallmark characteristics of astrogliosis both in vitro and in
vivo (see Figure 2).
The first evidence in this respect dates back to 1987
when Kim and Rathbone were purifying from brain
proteins that stimulated proliferation of cultured chick-brain
astrocytes. They isolated a potently mitogenic fraction that
was not a protein, and chemical analysis identified it as 50-
GMP. Rathbone and his colleagues soon determined that
guanosine, adenosine and their respective 50-mono-, di- and
triphosphate derivatives also stimulated proliferation and
DNA synthesis of chick astrocytes in vitro (see [44] and
references therein). Simultaneously, Neary, Norenberg and
colleagues, observed stellation and increases in GFAP
content within 1 h of exposure of rat cerebral cortical
astrocytes to 100 μM ATP. After 72-h treatment with 1 mM
ATP, DNA synthesis was increased three- to four-fold (see
[44] and references therein).
As a follow-up of these initial observations, we
determined the ability of the hydrolysis-resistant ATP
analog α,βmeATP to influence both proliferation and
differentiation of primary rat striatal astrocytes in culture.
Exposure to α,βmeATP increased the percentage of
bromodeoxyuridine-positive cells, suggesting increased
proliferation [45]. Moreover, this nucleotide also induced
a concentration-dependent increase of GFAP-positive as-
trocytic processes [46]. Interestingly, the effects induced by
the ATP analogue were quantitatively similar to those
produced by basic fibroblast growth factor (bFGF), a
known trigger of reactive astrogliosis. In fact, both ATP
and the polypeptide growth factor promoted maturation of
astrocytes towards a more differentiated phenotype charac-
terised by longer and thicker astrocytic processes [46]. In
subsequent studies, similar effects were obtained with other
nucleotides, such as ATP, adenosine 50-O-(2-thiodiphos-
phate) (ADPβS), 2meSATP, βγmeATP and UTP. Nucleo-
tide-induced astrogliosis was inhibited by pertussis toxin
(suggesting the involvement of a G-protein-coupled P2Y
receptor) and by several typical P2 receptor antagonists,
such as suramin and PPADS, but not by P2 receptor
antagonists that preferentially block P2X receptors, such as
20,30-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) [47, 48].
Importantly, the relevance of these in vitro findings to in
vivo reactive astrogliosis was confirmed by Franke and
coworkers [49] while investigating in the nucleus accum-
bens of rats the morphological effects induced by local
application of P2X and P2Y ligands. A strong mitogenic
effect was induced on astrocytes by ADPβS, 2meSATP,
α,βmeATP and, to a smaller extent, UTP-γS. This paper
was, indeed, the first to confirm that effects induced by
extracellular nucleotides in in vitro systems do have a
functional significance for in vivo gliosis, thus validating
the studies on cultured cells as adequate experimental
models to investigate the roles of P2 receptors in reactive
astrogliosis.
Transduction pathways involved in membrane-to-nucleus
signalling at the basis of nucleotide-induced astrogliosis
In 1997, we observed that at very early times (15 min) after
nucleotide challenge, cultured astrocytes released AA, as
shown by measurement of radioactivity in the culture
medium of cells previously labelled with [
3H]-AA [47].
This suggested that activation of phospholipase A2 (PLA2)
could be involved in the long-term functional effects
evoked by extracellular nucleotides. Consistently, exoge-
nously added AA markedly elongated astrocytic processes
[47], as did the inflammatory prostaglandin E2 (the major
AA metabolite in the brain) [50]. In line with these
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dexamethasone) prevented both the early nucleotide-in-
duced [
3H]-AA release and the associated long-term
morphological changes [47]. These effects were highly
specific for the purinergic system since in the same cells
inhibition of PLA2 had no effect on astrocytic elongation
induced by classical growth factors such as bFGF [47]. In
1999, we demonstrated that exposure of rat primary
astrocytes to NS-398, a selective inhibitor of the inducible
mitogen-stimulated cyclooxygenase-2 (COX-2), signifi-
cantly prevented P2Y receptor-mediated reactive astroglio-
sis [50]. Subsequent RT-PCR and Western blot analysis
showed that nucleotide-induced gliosis is indeed accompa-
nied by the de novo synthesis of COX-2 [50]. COX-2 up-
regulation was fully prevented by PPADS, thus confirming a
role for P2 receptors. Globally, these data suggest that
nucleotides induce astrocytes to release AA, which is then
metabolised by COX-2 to PGE2, which, in turn, likely
represents the AA product mediating nucleotide-induced
reactive astrogliosis.
Due to the large heterogeneity of P2 receptors in
astrocytes (see above and [35]), it may well be that
activation of the signalling cascade culminating in reactive
astrogliosis involves more that one P2 receptor or requires
interaction between different receptor subtypes, as also
suggested by studies performed in vivo [49].
The receptor-to-nucleus signalling cascade responsible
for nucleotide-induced reactive gliosis in rat primary
astrocytes has been dissected in detail and represents one
of the few examples of characterised gene transcriptional
control by P2 receptors. In our experimental model,
stimulation of P2Y receptors on astrocytes led to activation
of extracellular-regulated kinases 1/2 (ERK1/2) via multiple
parallel signalling pathways involving Gi/o protein-depen-
dent and calcium-independent stimulation of phosphatidyl-
choline phospholipase C (PC-PLC) and/or phospholipase D
(PLD), with consequent activation of the Ras/Raf system
[51]. Involvement of extracellular nucleotides and ERK1/2
in activation of astrocytes has been also confirmed in
another experimental model of gliosis: stretch-induced
astrocyte injury. Application of a rapid and reversible
stretch-induced injury to cultured astrocytes resulted in
immediate ERK1/2 activation, which was already maximal
after 10 min [52]. ERK activation was prevented by apyrase
and P2 receptor antagonists, suggesting that injury causes
r e l e a s eo fA T P ,w h i c hm a yi nt u r na u t o c r i n a l l ya n d
heterocrinally signal on astrocytes and stimulate ERK1/2
activity. Studies with various P2 receptor antagonists
indicated that in this experimental model, activation of
P2Y1 and P2X2 receptor subtypes might be particularly
important for the detected effects. Besides ERKs, in rat
cortical astrocytes, P2X and P2Y agonists may also
Figure 2 Modulation of brain inflammation by extracellular
nucleotides. Traumatic and/or ischaemic events lead to the massive
release of astrocytic ATP, which is rapidly degraded to ADP and
maybe other nucleotides. Extracellular nucleotides activate P2Y
and P2X receptors either paracrinally (1) or autocrinally (2), leading
to modulation of gene expression. Several pro-inflammatory and
anti-apoptotic genes have been demonstrated to be specifically up-
or down-regulated, which in turn results in astrocytic proliferation
and growth (reactive astrogliosis). Reactive astrocytes also synthe-
sise and release neurotrophins, pleiotrophins, cytokines, and small
signalling molecules [e.g., nitric oxide (NO)], which can modulate
neuronal and microglial cell survival and their reaction to noxious
stimuli. Extracellular nucleotides can also directly activate iono-
tropic or metabotropic receptors expressed by cell types other than
astrocytes (e.g., neurons and microglia), thus further contributing
to the development of a first inflammatory line of defence against
spreading of brain damage. Nevertheless, a chronic, sustained, and
out-of-control inflammatory reaction may result in brain cell loss,
and development of neurodegenerative events (see text for more
details). GDNPF glial-derived neurite-promoting factor, IP-10 inter-
feron-inducible protein 10, LIF, leukaemia inhibitory factor NT
neurotrophin
Purinergic Signalling (2006) 2: 595–604 601stimulate Akt/protein kinase B system, another family of
protein kinases that has been implicated in cell growth and
survival, in angiogenesis and glycogen synthesis [53, 54].
In astrocytes, a number of adenine and uracil nucleotides
induced Akt phosphorylation: pertussis toxin inhibited ATP
and UTP- (but not BzATP-) induced effects, suggesting a
role for P2X7 and P2Y receptors [53, 54]. At present, it is
not completely clear if signalling via ERK and Akt may
represent two independent pathways of gliosis; however,
pharmacological data suggest that not all P2 receptor
antagonists that effectively inhibit ERK also inhibit Akt,
suggesting involvement of either one of both pathways,
depending upon type, strength and length of the insult.
Modulation of gene expression by extracellular nucleotides
in reactive gliosis
Both the ERK and the Akt pathways are known to
influence gene expression through phosphorylation/activa-
tion of transcriptional factors [55]. Evidence has accumu-
lated to suggest induction of specific gene families in glial
cells upon exposure to extracellular nucleotides and
activation of P2 receptors. One of the first evidences in
this respect dates back to 1997, when we reported nuclear
accumulation of the fos and jun proteins upon exposure of
striatal astrocytes to nucleotides [47]. At that time, these
proteins were already known to dimerise and form activated
AP-1 transcriptional factors that can modulate gene
expression by binding to specific sequences on the
promoter regions of many genes. In line with this
hypothesis, a few years later, we demonstrated that
exposure of cultured astrocytes to nucleotides resulted in a
time-dependent increase in DNA binding activity of AP-1
[51]. In the same experiments, extracellular nucleotides also
increased DNA binding of nuclear factor kappa B (NF-kB),
another transcriptional factor crucially involved in several
inflammatory events including reactive astrogliosis. The
temporal profile of AP-1- and NF-kB-induced DNA
binding, which was significantly increased 30 min after
nucleotide addition to cultures and reached a maximal peak
at 1 h, was consistent with the timing of ERK1/2 activation,
the latter already being maximally activated after a 10-min
exposure to purine analogs [51]. Globally, these data
demonstrated a causal relationship between ERK1/2 and
binding of transcriptional factors to DNA, suggesting a
molecular pathway for regulation of gene expression by
extracellular nucleotides. Importantly, these data are also
consistent with results obtained on human foetal astrocytes,
where extracellular nucleotides potentiate IL-1β-induced
NF-kB and AP-1 activation, nuclear translocation and DNA
binding [56]. Interestingly enough, pharmacological data
indicated involvement of distinct P2 receptors in the
activation of these two families of transcriptional factors.
In particular, ATP and ADP were equipotent in inducing
NF-kB activation (followed by BzATP, with no effect of
UTP) whereas ADP was the most potent trigger for AP-1
activation (followed by ATP, with no effect by either
BzATP or UTP). Besides indicating different roles for
different P2 receptors in modulation of IL-1β-mediated
signal transduction, these results suggest highly specific
effects of extracellular nucleotides on gene transcription
(see also below).
More details on the gene families regulated by P2
receptors in astroglial cells have been recently provided by
Chorna et al. [57]. These authors showed that in 1321N1
astrocytoma cells expressing P2Y2 receptors, acute treat-
ment with UTP upregulated anti–apoptotic genes Bcl-2 and
Bcl-XL and downregulated the proapoptotic gene Bax. UTP
also upregulated a number of genes for neurotrophins,
neuropeptides and growth factors (see also Figure 2). This
pattern of gene expression clearly indicated activation of
neuroprotective mechanisms; this conclusion is further
confirmed by the demonstration that cultured media from
UTP-treated cells stimulated neurite outgrowth in PC-12
cells. In line with these findings, activation of P2Y6 in
human astrocytoma cells prevented TNFα-induced apopto-
sis and inhibited TNFα-induced activation of caspase-3 and
caspase-8 [58]. Although all these results have been
obtained in cell lines expressing recombinant P2 receptors,
they globally suggest that these receptors may mediate a
protective mechanism and that the net effect of purine-
induced gliosis may be beneficial. There may even be some
novel, yet-uncharacterised neuroprotective purinergic recep-
tors. In fact, besides releasing adenine nucleotides, astro-
cytes have been shown to release guanine-based purines
under basal and hypoxia conditions [59–61]. Guanosine is
antiapoptotic for neuroblastoma cells and also protects
astrocytes from apoptosis via upregulation of Bcl-2 [61].
The mechanism at the basis of guanosine protective effects
are still unknown but activation of a novel guanosine-
specific receptor may be involved. Globally, these findings
are consistent with results indicating increased ectonucleo-
tidase expression in focal cerebral ischaemia [62]. In
particular, data indicated an up-regulation of the capacity
for hydrolysis of nucleotides within tissue adjacent to the
infarcted area, suggesting that nucleotide concentrations at
the site of injury may crucially regulate the onset and
development of reactive and repair mechanisms.
The large variety of genes that have been reported to be
induced by extracellular nucleotides in astroglial cells is
summarised in Figure 2. It is evident that some genes are
increased and some other genes are decreased, which
suggests a high degree of specificity and a role for P2
receptors in fine-tuning gene transcription in inflammatory
responses. It is also evident that several neurotrophins are
induced by extracellular nucleotides and that both proin-
602 Purinergic Signalling (2006) 2: 595–604flammatory and antiinflammatory genes are induced. Al-
though this may seem puzzling, when we interpret these
effects, we should always remember that in some cases,
inflammatory molecules are needed to protect cells and
restore function [41]. In many organs, including the brain,
inflammation is likely to start as a time- and site-specific
defence mechanism aimed at eliminating irreversibly dam-
aged or potentially dangerous cells in order to save energy
and space for cells that still retain a chance of recovery.
When it becomes chronic, inflammation could evolve into a
destructive and uncontrolled reaction. Thus, failure to
resolve this initial beneficial response could lead to a vicious
and anarchic state of chronic activation resulting in brain cell
damage and loss [41]. Accumulated data suggest that in a
similar way, we should interpret purine-induced gliosis as a
defence mechanism that originates to protect neurons from
cytotoxic and ischemic insults. Dysregulation of purine-
induced gliosis upon chronic inflammatory conditions may
be at the basis of the reported deleterious effects induced by
purines and pyrimidines under certain experimental para-
digms [63]. On this basis, understanding molecular mech-
anisms and the timing of nucleotide-induced astrogliosis
may help exploit the beneficial neuroprotective features of
reactive astrocytes while attenuating their harmful proper-
ties.
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